Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Prevalence of Obesity in Obstructive Sleep Apnea
Apnimed Completes Enrollment in Ph3 LunAIRo Study of AD109, Potential 1st Nighttime Oral Tx for Obstructive Sleep Apnea; Presents Study Design at ATS2024
Apnimed Named 2024 Best Places to Work Company by the Boston Business Journal
Apnimed to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Apnimed to Participate in Upcoming Leerink Partners Global Biopharma Conference
Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference
Apnimed, which has a novel sleep apnea drug in Phase III, is considering a potential IPO in the second half of this year even as biotech entries to Wall Street have started to slow.
Apnimed Announces New Leadership Appointments as It Builds Commercial & HR Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for OSA
Apnimed named a new chief commercial officer on Monday, tapping Graham Goodrich, a veteran biopharma marketing executive, to start building out a team to commercialize its oral sleep apnea candidate now in Phase III studies.
-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- Part of a two-study...